These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19909586)

  • 1. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study.
    Isik AZ; Caglar GS; Sozen E; Akarsu C; Tuncay G; Ozbicer T; Vicdan K
    Reprod Biomed Online; 2009 Oct; 19(4):472-7. PubMed ID: 19909586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis.
    Oliveira JB; Baruffi R; Petersen CG; Mauri AL; Cavagna M; Franco JG
    Reprod Biol Endocrinol; 2010 Sep; 8():107. PubMed ID: 20825643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotrophin-releasing hormone antagonists for assisted conception.
    Al-Inany H; Aboulghar M
    Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocol.
    Cunha Filho JS; Terres LF; Holanda F; Freitas F; Glitz C; Genro VK; Arbo E
    J Assist Reprod Genet; 2007 Aug; 24(8):326-30. PubMed ID: 17636446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of oestradiol and progesterone to support luteal phase in antagonist intracytoplasmic sperm injection cycles of normoresponder women: a case-control study.
    Çakar E; Tasan HA; Kumru P; Cogendez E; Usal NT; Kutlu HT; Özkaya E; Eser SK
    J Obstet Gynaecol; 2020 Feb; 40(2):264-269. PubMed ID: 31455122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
    Ata B; Yakin K; Balaban B; Urman B
    Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study.
    Friedler S; Gilboa S; Schachter M; Raziel A; Strassburger D; Ron El R
    Reprod Biomed Online; 2006 Jan; 12(1):27-32. PubMed ID: 16454930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH agonist administration as luteal support on the transfer day of single blastocyst in dual-triggered cycles.
    Demir A; Köse C; Şahin Güleç E; Türkmen P; Töz E; Peker N
    Ginekol Pol; 2023; 94(5):374-388. PubMed ID: 35997216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial.
    Fusi FM; Brigante CM; Zanga L; Mignini Renzini M; Bosisio C; Fadini R
    Reprod Biol Endocrinol; 2019 Nov; 17(1):103. PubMed ID: 31783862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
    Yu LP; Liu N; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.